Alfuzosin

Summary

Alfuzosin (CHEMBL709) is an approved small-molecule antineoplastic agent (ATC G04CA01) targeting ADRA1A, ADRA1B, and ADRA1D; indicated across 7 conditions including benign prostatic hyperplasia and prostatitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G04CA01
• Targets: 3 (ADRA1A, ADRA1B, ADRA1D)
• Indications: 7 conditions
• Clinical trials: 34
• Chemistry: 389.4 Da · C19H27N5O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL709
Name	Alfuzosin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	2092
ChEBI	CHEBI:51141
ATC	G04CA01
Molecular formula	C19H27N5O4
Molecular weight	389.4
InChIKey	WNMJYKCGWZFFKR-UHFFFAOYSA-N

SMILES: CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC

IUPAC name: N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide

Pharmacological roles (ChEBI): antineoplastic agent, antihypertensive agent, α-adrenergic antagonist.

Also known as: Alfuzosin, Alfuzosina, Alfuzosine, NSC-760065, SID26719847, SID26749009, SID90341616, SID26749010, SID50107503, SID50107504, alfuzosin, ALFUSOZINE

Parent form; salt/anhydrous children: CHEMBL1723

Patent coverage: 1,924 distinct patent families (6,601 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 6,547 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ADRA1A	α1A-adrenoceptor	Antagonist	8.1		P35348
ADRA1B	α1B-adrenoceptor	Antagonist	8.6	0%	P35368
ADRA1D	α1D-adrenoceptor	Antagonist	8.4	0.2%	P25100

Broader ChEMBL bioactivity targets: 22 (assay-derived). Sample: Lysine-specific demethylase 4E, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Adrenergic receptor alpha-1, Acetylcholinesterase, Sodium-dependent noradrenaline transporter, Alpha-1D adrenergic receptor, Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, D(3) dopamine receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Alpha-galactosidase A, Lysosomal alpha-glucosidase, Alpha-1B adrenergic receptor, Alpha-1A adrenergic receptor, Alpha-1D adrenergic receptor, Aldehyde dehydrogenase 1A1, 3-hydroxyacyl-CoA dehydrogenase type-2.

Bioactivity

ChEMBL activities: 19 potent at pChembl ≥ 5 of 36 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRA1B	8.55	Ki	2.8	nM	CHEMBL_ACT_323086
ADRA1D	8.5	Ki	3.16	nM	CHEMBL_ACT_300803
P23944	8.46	Ki	3.5	nM	CHEMBL_ACT_323085
ADRA1D	8.44	Ki	3.6	nM	CHEMBL_ACT_323084
P15823	8.31	Kd	4.9	nM	CHEMBL_ACT_860949
ADRA1A	8.09	Ki	8.2	nM	CHEMBL_ACT_323088
ADRA1A	8	Ki	10	nM	CHEMBL_ACT_300801
ADRA1B	8	Ki	10	nM	CHEMBL_ACT_300802
ADRA1B	7.92	Ki	12	nM	CHEMBL_ACT_323087
ACHE	7.75	IC50	18	nM	CHEMBL_ACT_18570057
ADRA1D	7.64	IC50	23	nM	CHEMBL_ACT_24959137
P18130	7.64	Ki	23	nM	CHEMBL_ACT_323089
P43140	7.61	Kd	24.55	nM	CHEMBL_ACT_860948
ADRA1A	7.42	AC50	38	nM	CHEMBL_ACT_25218096
ADRA1A	7.1	AC50	79.7	nM	CHEMBL_ACT_25137951
ADRA1A	6.66	Kd	218.8	nM	CHEMBL_ACT_860950
ADRA2C	6.09	AC50	810	nM	CHEMBL_ACT_25147912
ADRA2A	5.17	AC50	6800	nM	CHEMBL_ACT_25219928
ADRA2B	5.05	AC50	8900	nM	CHEMBL_ACT_25143737

Target pathways

Aggregated over 3 target gene(s): ADRA1A, ADRA1B, ADRA1D.

Top Reactome pathways

9 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	3	ADRA1A, ADRA1B, ADRA1D
Signaling by GPCR	3	ADRA1A, ADRA1B, ADRA1D
Class A/1 (Rhodopsin-like receptors)	3	ADRA1A, ADRA1B, ADRA1D
Amine ligand-binding receptors	3	ADRA1A, ADRA1B, ADRA1D
GPCR downstream signalling	3	ADRA1A, ADRA1B, ADRA1D
Adrenoceptors	3	ADRA1A, ADRA1B, ADRA1D
G alpha (q) signalling events	3	ADRA1A, ADRA1B, ADRA1D
G alpha (12/13) signalling events	3	ADRA1A, ADRA1B, ADRA1D
GPCR ligand binding	3	ADRA1A, ADRA1B, ADRA1D

Dominant GO biological processes

GO term	Targets
signal transduction	3
G protein-coupled receptor signaling pathway	3
phospholipase C-activating G protein-coupled receptor signaling pathway	3
positive regulation of cytosolic calcium ion concentration	3
cell-cell signaling	3
positive regulation of MAPK cascade	3
adenylate cyclase-activating adrenergic receptor signaling pathway	3
neuron-glial cell signaling	3
adrenergic receptor signaling pathway	3
positive regulation of cardiac muscle hypertrophy	2
intracellular signal transduction	2
positive regulation of vasoconstriction	2
regulation of muscle contraction	2
regulation of vasoconstriction	2
regulation of cardiac muscle contraction	2

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
benign prostatic hyperplasia	4	MONDO:0010811	EFO:0000284

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
prostatitis	3	MONDO:0005280	EFO:0003830
nephrolithiasis	3	MONDO:0008171	EFO:0004253
constipation disorder	2	MONDO:0002203	HP:0002019
multiple sclerosis	2	MONDO:0005301	MONDO:0005301

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 34.

Phase distribution

Phase	Trials
PHASE3	14
PHASE4	11
PHASE2	3
Not specified	3
PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00280605	PHASE4	COMPLETED	ALF-ONE : ALFuzosin ONcE Daily
NCT00401661	PHASE4	COMPLETED	Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin
NCT00427882	PHASE4	COMPLETED	Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study
NCT00451061	PHASE4	UNKNOWN	The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones
NCT00486785	PHASE4	COMPLETED	SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin
NCT00542165	PHASE4	COMPLETED	Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy
NCT00575913	PHASE4	COMPLETED	Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study
NCT00637715	PHASE4	COMPLETED	Once Daily Given Alfuzosin in the Treatment of BPH
NCT00696761	PHASE4	COMPLETED	The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients
NCT00836823	PHASE4	COMPLETED	Evaluation of Symptom-specific Goal Achievement
NCT03144596	PHASE4	COMPLETED	The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil
NCT00029822	PHASE3	COMPLETED	Clinical Trial in Males With BPH (Enlarged Prostate)
NCT00064649	PHASE3	TERMINATED	Minimally Invasive Surgical Therapy for BPH
NCT00103402	PHASE3	COMPLETED	Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
NCT00290030	PHASE3	COMPLETED	ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH
NCT00388271	PHASE3	WITHDRAWN	Use of Alfuzosin in Stone Treatment With ESWL
NCT00399464	PHASE3	COMPLETED	Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia
NCT00453908	PHASE3	TERMINATED	Alfuzosin Versus Placebo in Acute Urinary Retention
NCT00454402	PHASE3	TERMINATED	ALF-STONE: Alfuzosin in Uretheric Stones
NCT00540891	PHASE3	COMPLETED	The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score
NCT00549939	PHASE3	COMPLETED	Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction
NCT00576823	PHASE3	COMPLETED	Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology
NCT00629720	PHASE3	COMPLETED	Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology
NCT00688948	PHASE2/PHASE3	TERMINATED	Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)
NCT00713739	PHASE3	UNKNOWN	Alfuzosin for Medical Expulsion Therapy of Ureteral Stones
NCT00893113	PHASE3	COMPLETED	An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms
NCT00336921	PHASE2	COMPLETED	Alfuzosin for Treating Acute Urinary Retention
NCT00679315	PHASE2	COMPLETED	Efficacy and Safety of Alfuzosin for the Treatment of Voiding Dysfunction in Female
NCT01834729	PHASE2	COMPLETED	Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions
NCT02266537	PHASE1	COMPLETED	Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers
NCT06316336	PHASE1	UNKNOWN	Multiple Dose, Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets Under Fed Conditions
NCT00256399	Not specified	COMPLETED	Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)
NCT00583258	Not specified	WITHDRAWN	A Randomized Study of Whether Alfuzosin(Xatral) Helps in the Passage of Kidney Stones
NCT02977832	Not specified	COMPLETED	Clinical Results of Odyliresin (Iresine Celosia) in Symptomatic Benign Prostatic Hyperplasia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

571 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
AMLODIPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
APRACLONIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
ASENAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
ATENOLOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
AZELASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
BRIMONIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
BUSPIRONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
CARIPRAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
CISAPRIDE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
CLONIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
CLOZAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
DEXMEDETOMIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
DOPAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
DOXAZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
EBASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
EPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
FENOLDOPAM	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
HALOPERIDOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
INDACATEROL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
INDORAMIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
ISOPROTERENOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
LABETALOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
MOXISYLYTE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
NAFTOPIDIL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
NEFAZODONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
NOREPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
OLANZAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
OXYMETAZOLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
PHENTOLAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
PRAZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
QUETIAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
RISPERIDONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
SERTINDOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
SILODOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
TAMSULOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
TEGASEROD	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
TERAZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
TERFENADINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
TOLAZOLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
VERAPAMIL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
VILAZODONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
XYLOMETAZOLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
ZIPRASIDONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
BUNAZOSIN	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D
IDAZOXAN	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D
LATREPIRDINE	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D
MEDETOMIDINE	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D
YOHIMBINE	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D
ABANOQUIL	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
CIRAZOLINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
DEXNIGULDIPINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
IPSAPIRONE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
MAZAPERTINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
NIGULDIPINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
PIPEROXAN	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
PIZOTYLINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
SPIRAMIDE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
SPIROXATRINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
TASIPIMIDINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
UPIDOSIN	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
ZOTEPINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1D
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
AMOXAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
APOMORPHINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
BENZTROPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
CARVEDILOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
CINNARIZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
CITALOPRAM	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
CLEMASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
DAPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
DOBUTAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
DOMPERIDONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
DOXEPIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
ERGOTAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
FENTANYL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
GUANABENZ	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
GUANFACINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
IMIQUIMOD	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
KETOTIFEN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
LOPERAMIDE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B
LUMATEPERONE TOSYLATE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B
MAPROTILINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
MEPAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
MIANSERIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
PERGOLIDE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D
PHENYLEPHRINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1D